CLINICAL_TRIALS
ClinicalTrials.gov record update
T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02957968
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:29:07.220992+00:00
- Published At
- 2023-11-09T00:00:00+00:00
- Record Updated At
- 2026-04-21
- Results Posted At
- 2023-11-09
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Breast Adenocarcinoma", "Estrogen Receptor- Negative Breast Cancer", "Estrogen Receptor-positive Breast Cancer", "HER2/Neu Negative", "Invasive Breast Carcinoma", "Progesterone Receptor Negative", "Progesterone Receptor Positive Tumor", "Stage II Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Triple-negative Breast Carcinoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-21"- protocolSection.identificationModule.nctId
"NCT02957968"- protocolSection.identificationModule.officialTitle
"T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-11-09"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.